Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

•Many inflammation-related markers are associated with response to nivolumab in HCC.•Many inflammatory signature scores within tumour samples are associated with survival.•Lower ratios of systemic inflammation markers are associated with clinical benefit.•Patients with HCC demonstrated positive responses regardless of AFP and viral dynamics. Background & AimsNivolumab, a programmed death (PD)-1 (PD-1) inhibitor, led to durable responses,...